AR117941A2 - Métodos para producir suspensión de aripiprazol - Google Patents

Métodos para producir suspensión de aripiprazol

Info

Publication number
AR117941A2
AR117941A2 ARP180103082A ARP180103082A AR117941A2 AR 117941 A2 AR117941 A2 AR 117941A2 AR P180103082 A ARP180103082 A AR P180103082A AR P180103082 A ARP180103082 A AR P180103082A AR 117941 A2 AR117941 A2 AR 117941A2
Authority
AR
Argentina
Prior art keywords
suspension
aripiprazole
machine
dispersing machine
methods
Prior art date
Application number
ARP180103082A
Other languages
English (en)
Original Assignee
Otsuka Pharma Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Otsuka Pharma Co Ltd filed Critical Otsuka Pharma Co Ltd
Publication of AR117941A2 publication Critical patent/AR117941A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Dispersion Chemistry (AREA)
  • Psychiatry (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)

Abstract

Un método para producir una suspensión de aripiprazol, donde el aripiprazol tiene un tamaño de partícula medio de 1 hasta 10 mm, comprendiendo el método los pasos de: (a) combinar aripiprazol a granel y un vehículo para formar una suspensión primaria; (b) someter la suspensión primaria a una primera pulverización utilizando por ej., una máquina de pulverización de alto cizallamiento, una máquina de dispersión que aplica fuerza de corte a un material a ser procesado, un molino coloide, una máquina de dispersión ultrasónica, o una máquina de dispersión emulsionante del tipo chorro a elevada presión para formar una suspensión secundaria; y (c) someter la suspensión secundaria a una segunda pulverización utilizando por ej., una máquina de dispersión emulsionante del tipo chorro a elevada presión para formar una suspensión final estéril; y un método para producir una formulación liofilizada a partir de la suspensión de aripiprazol.
ARP180103082A 2007-07-31 2018-10-23 Métodos para producir suspensión de aripiprazol AR117941A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2007200088 2007-07-31

Publications (1)

Publication Number Publication Date
AR117941A2 true AR117941A2 (es) 2021-09-08

Family

ID=39816777

Family Applications (2)

Application Number Title Priority Date Filing Date
ARP080103307A AR067747A1 (es) 2007-07-31 2008-07-30 Metodos para producir suspension de aripiprazol y formulacion liofilizada
ARP180103082A AR117941A2 (es) 2007-07-31 2018-10-23 Métodos para producir suspensión de aripiprazol

Family Applications Before (1)

Application Number Title Priority Date Filing Date
ARP080103307A AR067747A1 (es) 2007-07-31 2008-07-30 Metodos para producir suspension de aripiprazol y formulacion liofilizada

Country Status (28)

Country Link
US (6) US9457026B2 (es)
EP (1) EP2170279B1 (es)
JP (1) JP4879349B2 (es)
KR (1) KR101546106B1 (es)
CN (1) CN101801342B (es)
AR (2) AR067747A1 (es)
BR (1) BRPI0815382A2 (es)
CA (1) CA2695178C (es)
CO (1) CO6290634A2 (es)
CY (1) CY1120165T1 (es)
DK (1) DK2170279T3 (es)
ES (1) ES2661037T3 (es)
HR (1) HRP20180295T1 (es)
HU (1) HUE036214T2 (es)
IL (2) IL244186A0 (es)
LT (1) LT2170279T (es)
MX (1) MX2010001311A (es)
MY (1) MY152789A (es)
NO (1) NO2170279T3 (es)
NZ (1) NZ582415A (es)
PL (1) PL2170279T3 (es)
PT (1) PT2170279T (es)
RU (1) RU2483711C2 (es)
SI (1) SI2170279T1 (es)
TW (1) TWI410255B (es)
UA (1) UA97286C2 (es)
WO (1) WO2009017250A1 (es)
ZA (1) ZA201000307B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009017250A1 (en) * 2007-07-31 2009-02-05 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation
PT105058B (pt) 2010-04-21 2013-04-17 Hovione Farmaciencia S A Processo para processamento de partículas de ingredientes activos farmacêuticos
BR112012028368B8 (pt) * 2010-08-24 2022-07-19 Otsuka Pharma Co Ltd Processo para prevenção de aglomeração de partículas de ingrediente ativo em uma suspensão, suspensão e composição de torta contendo derivado carbo estirila e óleo de silicone e/ou derivado de óleo de silicone
LT2667856T (lt) * 2011-01-24 2021-11-25 Otsuka Pharmaceutical Co., Ltd. Medicininė priemonė, kurioje yra sausos masės kompozicija, apimanti aripiprazolą kaip veikliąją sudedamąją dalį, ir sausos masės kompozicija, apimanti aripiprazolą kaip veikliąją sudedamąją dalį
JO3410B1 (ar) * 2011-06-07 2019-10-20 Otsuka Pharma Co Ltd تركيبة أريبيبرازول مجفف بالتبريد
KR101103011B1 (ko) * 2011-10-13 2012-01-05 (주)일신오토클레이브 스크루 형 고압 발생 장치
CN102524261B (zh) * 2011-12-16 2014-12-03 辽宁师范大学 一种强力生根剂纳米制剂、其制备方法及应用
CN102450269A (zh) * 2011-12-27 2012-05-16 辽宁师范大学 三唑酮纳米胶体悬浮剂及其制备方法
AR090775A1 (es) 2012-04-23 2014-12-03 Otsuka Pharma Co Ltd Preparado inyectable
JOP20200109A1 (ar) * 2012-04-23 2017-06-16 Otsuka Pharma Co Ltd مستحضر قابل للحقن
JP5341282B1 (ja) * 2012-06-29 2013-11-13 丸石製薬株式会社 アリピプラゾールの経口医薬製剤
EP2868319A4 (en) * 2012-06-29 2016-02-24 Maruishi Pharma ORAL PHARMACEUTICAL PREPARATION OF ARIPIPRAZOLE
JP6007169B2 (ja) * 2012-11-30 2016-10-12 大原薬品工業株式会社 アリピプラゾール無水物を含有する固形製剤の製造方法
US9655951B2 (en) * 2013-01-23 2017-05-23 Cartilast II LLC Preservation of the biological activity of undenatured type II collagen
US9051268B2 (en) 2013-04-30 2015-06-09 Otsuka Pharmaceutical Co., Ltd. Oral solid preparation comprising aripiprazole and method for producing oral solid preparation comprising aripiprazole
WO2017025930A1 (en) 2015-08-12 2017-02-16 Ftf Pharma Private Limited Oral solution of aripiprazole
CN106474058B (zh) * 2015-08-31 2020-01-07 南京诺瑞特医药科技有限公司 具有延长的保质期的阿立哌唑可注射悬浮液制剂
CA3030972A1 (en) 2016-07-28 2018-02-01 Mylan Laboratories Ltd Process for preparing sterile aripiprazole formulation
US10821200B2 (en) 2016-12-05 2020-11-03 Hyalo Technologies, LLC Method of sterilization of microparticles
CN108938578A (zh) * 2017-05-25 2018-12-07 万全万特制药（厦门）有限公司 阿立哌唑分散片及其制备方法
US20230310417A1 (en) * 2020-03-30 2023-10-05 Cipla Limited Injectable aripiprazole formulation
EP4043008A1 (en) 2021-02-15 2022-08-17 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Method for the preparation of a pharmaceutical composition comprising aripiprazole
CN115554253B (zh) * 2022-10-14 2024-03-29 浙江圣兆药物科技股份有限公司 一种平稳释药的注射用阿立哌唑冻干制剂及其制备方法
CN117281784B (zh) * 2023-11-24 2024-02-27 山东则正医药技术有限公司 一种阿立哌唑注射剂及其制备方法和应用

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB209551A (en) 1922-11-20 1924-01-17 William Mortimer Melmore Improvements in or relating to petrol and other cans
JPS54130587A (en) * 1978-03-30 1979-10-09 Otsuka Pharmaceut Co Ltd Carbostyryl derivative
CA1209477A (en) 1981-03-26 1986-08-12 Bruce E. Haeger Composition of matter comprising a lyophilized preparation of a penicillin derivative
JPS5832899A (ja) 1981-08-18 1983-02-25 Takeda Chem Ind Ltd オキセンドロン水性懸濁剤
US4352811A (en) * 1981-11-12 1982-10-05 Hoechst-Roussel Pharmaceuticals Inc. 3-(1-Substituted-4-piperidyl)-1,2-benzisoxazoles
IL68549A (en) * 1983-05-03 1988-05-31 Kit Medidont Ltd Method and instrument for measuring moisture
KR850004274A (ko) * 1983-12-13 1985-07-11 원본미기재 에리트로포이에틴의 제조방법
US4804663A (en) * 1985-03-27 1989-02-14 Janssen Pharmaceutica N.V. 3-piperidinyl-substituted 1,2-benzisoxazoles and 1,2-benzisothiazoles
JP2608788B2 (ja) 1988-10-31 1997-05-14 大塚製薬 株式会社 精神分裂病治療剤
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
FR2663223B1 (fr) 1990-06-14 1994-12-02 Af Aplicaciones Far Lab Forme galenique parenterale.
DE69112917T2 (de) * 1990-06-15 1996-05-15 Merck & Co Inc Kristallisationsverfahren zur Verbesserung der Kristallstruktur und -grösse.
IT1244880B (it) 1990-12-11 1994-09-12 Torre A Farmaceutici Formulazioni di amminoacidi liofilizzati contenenti glutammina, loro preparazione ed uso nell'alimentazione parenterale
US6193983B1 (en) * 1992-06-01 2001-02-27 The University Of Melbourne Equine herpesvirus glycoproteins
TW376319B (en) * 1993-04-28 1999-12-11 Janssen Pharmaceutica Nv Pharmaceutical composition containing risperidone pamoate and having a long acting activity for treating psychoses induced by the release of dopamine
DK0729357T3 (da) 1993-11-19 2005-06-06 Janssen Pharmaceutica Nv Mikroindkapslede 1,2-benzazoler
EP0762897B1 (en) 1994-06-02 2003-04-02 Elan Drug Delivery Limited Method of preventing aggregation of proteins/peptides upon rehydration or thawing
RU2082401C1 (ru) 1994-08-18 1997-06-27 Фармацевтическое акционерное общество "Ферейн" Способ получения лекарственной формы комбинированного препарата
US5510118A (en) * 1995-02-14 1996-04-23 Nanosystems Llc Process for preparing therapeutic compositions containing nanoparticles
US6165442A (en) * 1996-02-19 2000-12-26 Nycomed Imaging As Thermally stabilized ultrasound contrast agent
WO1998008489A1 (en) 1996-08-26 1998-03-05 Transgene S.A. Cationic lipid-nucleic acid complexes
US6297231B1 (en) * 1996-10-28 2001-10-02 Merck & Co., Inc. Stabilized carbapenem antibiotic compositions and method of making
GB9705588D0 (en) * 1997-03-18 1997-05-07 Anglia Research Foundation Stable particle in liquid formulations
GB9718986D0 (en) 1997-09-09 1997-11-12 Danbiosyst Uk Controlled release microsphere delivery system
ES2257041T3 (es) * 1998-03-30 2006-07-16 Jagotec Ag Composicion y metodo para preparar microparticulas de substancias insolubles en agua.
EP1100549B1 (en) * 1998-07-30 2007-03-07 Point Biomedical Corporation A novel excipient for the lyophilization of aqueous suspensions of microparticles
DE19857609A1 (de) 1998-12-14 2000-06-15 Hannelore Ehrenreich Verwendung von Erythropoietin zur Behandlung von cerebralen Ischämien des Menschen
US6455526B1 (en) * 1998-12-16 2002-09-24 Aventis Pharmaceuticals, Inc. Biodegradable polymer encapsulated pharmaceutical compositions and method for preparing the same
US6267989B1 (en) * 1999-03-08 2001-07-31 Klan Pharma International Ltd. Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions
WO2000072835A2 (en) * 1999-05-27 2000-12-07 El Khoury George F Topical application of muscarinic and opioid agents for treatment of tinnitus
JP2001187735A (ja) 2000-01-05 2001-07-10 Towa Yakuhin Kk 安定なニコランジル含有粉末の製造法
US6559128B1 (en) * 2000-01-21 2003-05-06 Northwestern University Inhibitors of G protein-mediated signaling, methods of making them, and uses thereof
RU2169574C1 (ru) 2000-01-27 2001-06-27 Кобатов Алексей Иванович Способ получения биопрепарата и сухой биопрепарат
WO2001058428A1 (en) 2000-02-10 2001-08-16 Alkermes Controlled Therapeutics, Inc. Method of preparing a sustained release composition
AU4949901A (en) 2000-03-27 2001-10-08 Scripps Research Inst Methods for inhibiting angiogenesis and tumor growth
WO2001080828A2 (en) 2000-04-20 2001-11-01 Rtp Pharma Inc. Improved water-insoluble drug particle process
US6495164B1 (en) * 2000-05-25 2002-12-17 Alkermes Controlled Therapeutics, Inc. I Preparation of injectable suspensions having improved injectability
JP2002241284A (ja) 2001-02-16 2002-08-28 Towa Yakuhin Kk 全身投与用アルガトロバン注射液
MY129350A (en) 2001-04-25 2007-03-30 Bristol Myers Squibb Co Aripiprazole oral solution
JP2003063965A (ja) * 2001-06-13 2003-03-05 Otsuka Pharmaceut Factory Inc 注射用シロスタゾール水性製剤
AU2002313236B2 (en) 2001-06-14 2007-07-26 Otsuka Pharmaceutical Co., Ltd. Medicinal compositions
ATE381924T1 (de) 2001-09-21 2008-01-15 Egalet As Feste dispersionen mit kontrollierter freisetzung von carvedilol
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
ITMI20020808A1 (it) * 2002-04-17 2003-10-17 Chiesi Farma Spa Procedimento per la preparazione di una sospensione sterile di particelle di beclometasone dipropionato da somministrare per inalazione
GB0216416D0 (en) 2002-07-15 2002-08-21 Novartis Ag Organic compounds
US20040258757A1 (en) * 2002-07-16 2004-12-23 Elan Pharma International, Ltd. Liquid dosage compositions of stable nanoparticulate active agents
NZ537995A (en) * 2002-08-20 2007-11-30 Bristol Myers Squibb Co Inclusion complex of aripiprazole in a substituted b-cyclodextrin
ITMI20022674A1 (it) 2002-12-18 2004-06-19 Chiesi Farma Spa Procedimento per la preparazione di formulazioni sterili a base di principi attivi farmaceutici cristallini micronizzati da somministrare come sospensioni acquose per inalazione.
CA2511523C (en) * 2002-12-31 2013-10-15 Nektar Therapeutics Pharmaceutical formulation with an insoluble active agent for pulmonary administration
WO2004064752A2 (en) 2003-01-22 2004-08-05 Alkermes Controlled Therapeutics, Inc. Method of preparing sustained release microparticles
JP2005022989A (ja) 2003-06-30 2005-01-27 Otsuka Pharmaceut Factory Inc 可溶化または分散化された難溶性化合物を含む組成物
US20050032811A1 (en) * 2003-08-06 2005-02-10 Josiah Brown Methods for administering aripiprazole
US6987111B2 (en) * 2003-08-06 2006-01-17 Alkermes Controlled Therapeutics, Ii Aripiprazole, olanzapine and haloperidol pamoate salts
TWI371274B (en) 2003-10-23 2012-09-01 Bristol Myers Squibb Co Process for making sterile aripiprazole of desired mean particle size
KR100931784B1 (ko) * 2003-10-23 2009-12-14 오츠카 세이야쿠 가부시키가이샤 방출조절성 멸균 아리피프라졸 주사제, 그 제조방법
WO2005041897A2 (en) * 2003-10-31 2005-05-12 Point Biomedical Corporation Reconstitutable microsphere compositions useful as ultrasonic contrast agents
US20050220887A1 (en) * 2004-01-20 2005-10-06 Alkermes Controlled Therapeutics, Inc. Method for milling frozen microparticles
WO2005089718A2 (en) * 2004-03-23 2005-09-29 Novartis Ag Pharmaceutical compositions
DE102005011786A1 (de) * 2005-03-11 2006-09-14 Pharmasol Gmbh Verfahren zur Herstellung ultrafeiner Submicron-Suspensionen
AU2006224759A1 (en) * 2005-03-17 2006-09-21 Synthon B.V. Process of making crystalline Type II aripiprazole
CA2622758A1 (en) * 2005-09-15 2007-03-29 Elan Pharma International, Limited Nanoparticulate aripiprazole formulations
EP1951197A4 (en) 2005-11-10 2011-12-21 Alphapharm Pty Ltd METHOD OF CHECKING THE PARTICLE SIZE
US20070148245A1 (en) * 2005-12-22 2007-06-28 Ilan Zalit Compressed solid dosage forms with drugs of low solubility and process for making the same
WO2009017250A1 (en) * 2007-07-31 2009-02-05 Otsuka Pharmaceutical Co., Ltd. Methods for producing aripiprazole suspension and freeze-dried formulation

Also Published As

Publication number Publication date
IL244186A0 (en) 2016-04-21
CO6290634A2 (es) 2011-06-20
UA97286C2 (ru) 2012-01-25
AU2008283251A1 (en) 2009-02-05
US20180185358A1 (en) 2018-07-05
CY1120165T1 (el) 2018-12-12
US20100196486A1 (en) 2010-08-05
PL2170279T3 (pl) 2018-05-30
CN101801342B (zh) 2012-07-11
KR101546106B1 (ko) 2015-08-20
LT2170279T (lt) 2018-03-12
KR20100057020A (ko) 2010-05-28
ZA201000307B (en) 2011-04-28
CA2695178A1 (en) 2009-02-05
US9457026B2 (en) 2016-10-04
EP2170279B1 (en) 2017-12-27
NZ582415A (en) 2012-05-25
US20240139177A1 (en) 2024-05-02
AR067747A1 (es) 2009-10-21
JP2010535151A (ja) 2010-11-18
US20210361646A1 (en) 2021-11-25
US20170035752A1 (en) 2017-02-09
RU2009149820A (ru) 2011-09-10
NO2170279T3 (es) 2018-05-26
PT2170279T (pt) 2018-04-06
CN101801342A (zh) 2010-08-11
HRP20180295T1 (hr) 2018-03-23
US20200246333A1 (en) 2020-08-06
CA2695178C (en) 2015-06-23
EP2170279A1 (en) 2010-04-07
RU2483711C2 (ru) 2013-06-10
MX2010001311A (es) 2010-04-21
DK2170279T3 (en) 2018-03-12
JP4879349B2 (ja) 2012-02-22
MY152789A (en) 2014-11-28
ES2661037T3 (es) 2018-03-27
HUE036214T2 (hu) 2018-06-28
IL244231A0 (en) 2016-04-21
TWI410255B (zh) 2013-10-01
SI2170279T1 (en) 2018-04-30
BRPI0815382A2 (pt) 2015-02-10
WO2009017250A1 (en) 2009-02-05
TW200922636A (en) 2009-06-01

Similar Documents

Publication Publication Date Title
AR117941A2 (es) Métodos para producir suspensión de aripiprazol
CL2016002869A1 (es) Un producto de tablero de fibra que comprende fibras, un material que contiene carbonato de calcio que tiene un tamaño de partícula medio de d50 desde 0,5 hasta 150,0 um, y un aglutinante; método de fabricacción del mismo; y uso de carbonato de calcio como reemplazo de fibras en un tablero de fibra
CL2021002249A1 (es) Composiciones de partículas de sílice mesoporosa para administración viral
MX2021012934A (es) Lipidos de amina ionizables y nanoparticulas lipidicas.
WO2006122223A3 (en) Strategies for delivery of active agents using micelles and particles
EP4302955A3 (en) Shaped abrasive particles and methods of forming same
NZ700875A (en) Pharmaceutical nanoparticles showing improved mucosal transport
CL2008001753A1 (es) Proceso para preparar biomasa solida para procesamiento de una mezcla acuosa que comprende triturar la biomasa, agregar un agente de dispersion y contactarla con un catalizador.
WO2014052883A3 (en) Composite materials formed by shear mixing of carbon nanostructures and related methods
BR112014015206A2 (pt) composições e métodos para fazer produtos de papel
ES2531066T3 (es) Un suplemento intraarticular para uso en el tratamiento de enfermedades y lesiones articulares
BR112012018417A2 (pt) método para dispersar nanotubos.
BR112014017241A8 (pt) processo para a preparação de um poliéter-éster poliol, poliéter-éster poliol, e, uso de um poliéter-éster poliol
MX2017014851A (es) Bebida a base de nuez hecha con nueces sin hornear.
WO2012003003A3 (en) Methods for preparing nanoformulations and systems for nano - delivery using focused acoustics
AR053677A1 (es) Proceso para elaborar lactosa utilizando tecnicas de pre- clasificacion y formulaciones farmaceuticas formadas a partir de ella
BR112013022431A2 (pt) derivado de polissacarídeo, forma de dosagem, processo para preparar uma forma de dosagem e uso de um derivado de polissacarídeo
AU2007270125A8 (en) Preservation and controlled delivery/release of spermatozoa
MX2016010037A (es) Nanosuspension de materiales naturales y metodo de preparacion del mismo.
EA201491174A1 (ru) Косметические композиции масло-в-воде
MX2023006604A (es) Lipidos cationicos ionizables y nanoparticulas lipidicas, y metodos de sintesis y uso de los mismos.
BR112018001439A2 (pt) aperfeiçoamentos em moinhos
BR112017014083A2 (pt) artigos abrasivos e métodos para formar os mesmos
WO2011006664A8 (de) VERFAHREN UND VORRICHTUNG ZUM TRENNSCHARFEN KLASSIEREN VON PARTIKELN NACH IHRER GRÖßE
AU2014226192A8 (en) Dry pharmaceutical compositions comprising active agent nanoparticles bound to carrier particles

Legal Events

Date Code Title Description
FC Refusal